← All trials
NCT06974786
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 8, 2025
- Primary completion
- Nov 30, 2032
- Completion date
- Apr 30, 2033
- First posted
- May 16, 2025
- Last posted
- Nov 6, 2025
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SCRI Development InnovationsLead sponsor
- PfizerCollaborator
- Colorado Blood Cancer InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.